The Nordic Group Acquires Rights to Trasylol® From Bayer HealthCare

Hoofddorp, Netherlands (ots/PRNewswire) -

Nordic Group announced today that it has reached an agreement
with Bayer HealthCare in which Nordic will acquire Trasylol(R)
(aprotinin injection) worldwide excluding the United States. Under
this agreement, Nordic will become the Marketing Authorization Holder
for aprotinin in the relevant Territories. This follows the opinion
of the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) from February 2012, recommending that
the marketing authorisation for aprotinin should be reinstated in the
European Union. The recommendation took into account a full review of
the benefits and risks of all antifibrinolytic medicines, which found
that the results of the study on which the suspension of aprotinin
was based were unreliable. This positive opinion is expected to be
ratified by the European Commission later in 2012. Nordic will be
managing global supplies of aprotinin in the relevant Territories.

About Aprotinin

The CHMP has recommended lifting the suspension for aprotinin in
the following indication:

Aprotinin is indicated for prophylactic use to reduce blood loss
and blood transfusion in adult patients who are at high risk of major
blood loss undergoing isolated cardiopulmonary bypass graft surgery
(i.e., coronary artery bypass graft surgery that is not combined with
other cardiovascular surgery). Aprotinin should only be used after
careful consideration of the benefits and risks, and the
consideration that alternative treatments are available. Since 2007
both Nordic (which was already marketing an aprotinin product) and
Bayer have maintained compassionate limited access programmes in some
16 countries. In September 2011, the marketing authorisation for
aprotinin was reinstated in Canada.

About Nordic Group BV

The Nordic Group is a privately owned, fast growing, fully
integrated, pan-European pharmaceutical company, with a strong focus
on the development and commercialization of niche hospital and orphan
products and services that cater to the specific needs of clients and
patients. In addition to its sales and marketing companies in 14
European countries, operating under the name of Nordic Pharma and
Nordic Drugs, the Nordic Group operates as well a number of
specialized Pharmaceutical Services companies, specialized in product
development, manufacturing, supply logistics, clinical studies and
regulatory activities. These companies are operating under the name
of Prague Clinical Services, QPharma, Disphar and Indeus. Since its
creation, Nordic has enjoyed an average growth of 20% in revenues,
and it pursues its expansion through organic growth and strategic
collaborations. Additional information can be obtained by visiting
Nordic Group's website at http://www.nordicpharmagroup.com.

Contacts at Nordic

Hans Schram, CEO, info@nordicpharma.com

Stéphane Altaba, Corporate Business Development Director,
busdev@nordicpharma.com , +33(0)1-53-63-88-77

ots Originaltext: Nordic Group BV
Im Internet recherchierbar: http://www.presseportal.de